Ticarcillin/Clavulanate

From WikEM
Jump to: navigation, search

Brand Discontinued in U.S

General

  • Type: Anti-Pseudomonal Penicillin
  • Dosage Forms:
  • Common Trade Names: Timentin

Adult Dosing

Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)

General

  • <60 kg
    • 200-300mg ticarcillin/kg/day IV divided q4-6 hours
    • First Dose:
    • Max: 18 g/day
  • ≥60 kg
    • 3.1 g every 4-6 hours
    • First Dose:
    • Max: 18 g/day

Pediatric Dosing

Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)

General (≥3 Months)

  • <60 kg
    • 200-300mg ticarcillin/kg/day IV divided q4-6 hours
    • First Dose: 50mg tiacarcillin/kg IV x 1
    • Max: 18g/day
  • ≥60 kg
    • 3.1 g q4-6 hours
    • Max: 18g/day

Special Populations

  • Pregnancy: B
  • Lactation: Use caution
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: Ticarcillin: 1.1 hours; Clavulanic acid: 1.1 hours
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep I
Strep. anginosus gp S
Enterococcus faecalis I
Enterococcus faecium I
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis I
C. jeikeium R
L. monocytogenes X2
Gram Negatives N. gonorrhoeae X2
N. meningitidis S
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos S
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii S
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. I
Pseudomonas aeruginosa S
Burkholderia cepacia X1
Stenotrophomonas maltophilia S
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp R
Mycoplasm pneumoniae R
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis S
Prevotella melaninogenica S
Clostridium difficile X1
Clostridium (not difficile) S
Fusobacterium necrophorum S
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2014